View ValuationMedicover 将来の成長Future 基準チェック /56Medicover利益と収益がそれぞれ年間25.1%と10.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に24.1% 23.1%なると予測されています。主要情報25.1%収益成長率23.13%EPS成長率Healthcare 収益成長19.4%収益成長率10.8%将来の株主資本利益率24.06%アナリストカバレッジGood最終更新日14 Nov 2025今後の成長に関する最新情報お知らせ • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.すべての更新を表示Recent updatesお知らせ • Jun 20KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital ArmKKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries.お知らせ • Oct 23Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University HospitalMedicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease.お知らせ • Oct 03Medicover AB (publ), Annual General Meeting, Apr 29, 2026Medicover AB (publ), Annual General Meeting, Apr 29, 2026.お知らせ • Jul 24+ 3 more updatesMedicover AB (publ) to Report Fiscal Year 2025 Results on Feb 10, 2026Medicover AB (publ) announced that they will report fiscal year 2025 results at 7:45 AM, Central European Standard Time on Feb 10, 2026お知らせ • Jun 19Medicover AB (Publ) Announces Executive ChangesMedicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service.お知らせ • Jun 03Medicover Announces Positive Interim Results from the DART Clinical StudyMedicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort.お知らせ • Apr 30+ 1 more updateMedicover AB (Publ) Approves Board ElectionsMedicover AB (publ) at its annual general meeting held on 29 April 2025, elected Michael Flemming and Claudia Olsson as new board member.お知らせ • Apr 10Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million.Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million on April 8, 2025. The transaction values CityFit at PLN 565 million (approximately €131 million) including assumed net debt with right-of-use liabilities and implies approximately a 7x LTM EBITDA multiple (excluding synergies). It will be EPS accretive from day one after completion. CityFit has generated the revenue for 2024 amounted to approximately €32 million (PLN 136.92 million). Following the acquisition, Medicover owns over 170 fitness clubs across Poland. CityFit’s staff will join the Medicover family. Medicover AB (publ) (OM:MCOV B) completed the acquisition of Cityfit Sp Z O O on April 8, 2025.お知らせ • Mar 22Medicover AB (publ) Proposes Dividend for 2024, Payable on 9 May 2025Medicover AB (publ) at its annual general meeting on 29 April 2025, board of directors proposed a dividend for 2024 of EUR 0.15 per share and 2 May 2025 as record date for dividend. Assuming this date will be the record date, Euroclear Sweden AB is expected to disburse dividends on 9 May 2025. The last day for trading in the company's share including the right to the dividend is 29 April 2025.お知らせ • Feb 13Medicover AB (Publ) Proposes Dividend for 2024Medicover AB (publ) announced that its board of directors proposed a dividend for 2024 of €0.15 (€0.12) per share.お知らせ • Feb 12Medicover AB (Publ) Announces CEO Changes, Effective 1 May 2025The Board of Directors of Medicover AB (publ) announced that John Stubbington will succeed Fredrik Rågmark as new CEO of the Medicover group from 1 May 2025. After 30 years with the Medicover group and 25 years as CEO, Fredrik Rågmark will step down from his operational role in Medicover by the end of April 2025 but will remain available to Medicover during 2025. John Stubbington, currently COO of Medicover'sHealthcare Services division, joined Medicover in 2010. Before joining Medicover, John held various positions within BUPA, the global health insurer, including nine years of working for their International division.お知らせ • Oct 30+ 3 more updatesMedicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025Medicover AB (publ) announced that they will report first half, 2025 results on Jul 24, 2025お知らせ • Oct 02Medicover AB (publ) Announces Nomination Committee for the AGM 2025Medicover AB (publ) publishes the nomination committee's composition for the annual general meeting in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding; Hans Ramel, NG Invest Beta AB; Jannis Kitsakis, Fjärde AP-Fonden; Sophie Larsén, AMF och AMF Fonder. AGM to be held on 29 April 2025. Proposals should be submitted to the nomination committee no later than 11 March 2025.お知らせ • Oct 01Medicover AB (publ), Annual General Meeting, Apr 25, 2025Medicover AB (publ), Annual General Meeting, Apr 25, 2025.お知らせ • Aug 14Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during fourth quarter of 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain - one of the leading brands within the Pepco Group (publ). Pepco Group is listed on the Warsaw stock exchange since 2021 with a market cap of over EUR 2.4 billion. Before Pepco, Anand held the position of head of finance at other retail chains such as Halfords and Argos. Anand Patel will replace Joe Ryan, who has served as CFO of Medicover for over 28 years and will be retiring, as announced last year.お知らせ • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.お知らせ • Jan 09Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024Medicover announced that Kamila Skorupinski will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services.お知らせ • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.お知らせ • Nov 04Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial OfficerJoe Ryan, CFO, has announced that after 28 years with Medicover he will retire from the company during 2024. Joe Ryan will continue in the role until a successor is in place, ensuring continuity. A search process has started.お知らせ • Sep 21Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024Medicover AB (publ) ("Medicover") publishes the nomination committee's composition for the annual general meeting in 2024. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 27 April 2023, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding, Hans Ramel, NG Invest Beta AB, Jannis Kitsakis, Fjärde AP-Fonden, Angelica Hanson, AMF och AMF Fonder.お知らせ • Sep 20Medicover AB (publ), Annual General Meeting, Apr 26, 2024Medicover AB (publ), Annual General Meeting, Apr 26, 2024.お知らせ • Jul 26+ 3 more updatesMedicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024Medicover AB (publ) announced that they will report Q1, 2024 results at 7:45 AM, Central European Standard Time on Apr 26, 2024お知らせ • Feb 18Medicover AB (publ) Proposes Dividend for 2022Medicover AB (publ) board of directors proposed a dividend for 2022 of €0.12 (€0.12) per share.お知らせ • Nov 03+ 2 more updatesMedicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023Medicover AB (publ) announced that they will report Q2, 2023 results on Jul 26, 2023お知らせ • Oct 22Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Medicover AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023業績と収益の成長予測OTCPK:MCVE.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20283,414178215441312/31/20273,006134196353612/31/20262,71399162299612/31/20252,39574-2626169/30/20252,32267166308N/A6/30/20252,25843157281N/A3/31/20252,17131148271N/A12/31/20242,09217140262N/A9/30/20241,99820122240N/A6/30/20241,91123116225N/A3/31/20241,82622113222N/A12/31/20231,7461895205N/A9/30/20231,682890205N/A6/30/20231,610575202N/A3/31/20231,548143186N/A12/31/20221,5101230170N/A9/30/20221,4893745182N/A6/30/20221,4555967195N/A3/31/20221,4428895205N/A12/31/20211,377102115217N/A9/30/20211,29993105202N/A6/30/20211,2269091176N/A3/31/20211,07652104176N/A12/31/20209982683155N/A9/30/20209301475141N/A6/30/2020879453122N/A3/31/20208841631100N/A12/31/2019844232487N/A9/30/2019796192879N/A6/30/201975119N/A86N/A3/31/201970920N/A85N/A12/31/201867222N/A74N/A9/30/201864328N/A75N/A6/30/201862026N/A61N/A3/31/201860023N/A55N/A12/31/201758019N/A50N/A9/30/201756010N/A40N/A6/30/20175409N/A36N/A3/31/20175226N/A31N/A12/31/20164974N/A26N/A12/31/20154168N/A29N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MCVE.Fの予測収益成長率 (年間25.1% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: MCVE.Fの収益 ( 25.1% ) はUS市場 ( 18.9% ) よりも速いペースで成長すると予測されています。高成長収益: MCVE.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: MCVE.Fの収益 ( 10.8% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。高い収益成長: MCVE.Fの収益 ( 10.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MCVE.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 24.1 %)成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/19 07:36終値2025/10/22 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medicover AB (publ) 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関null nullABG Sundal Colliernull nullABG Sundal Collier SponsoredKristofer Liljeberg-SvenssonCarnegie Investment Bank AB7 その他のアナリストを表示
お知らせ • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.
お知らせ • Jun 20KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital ArmKKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries.
お知らせ • Oct 23Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University HospitalMedicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease.
お知らせ • Oct 03Medicover AB (publ), Annual General Meeting, Apr 29, 2026Medicover AB (publ), Annual General Meeting, Apr 29, 2026.
お知らせ • Jul 24+ 3 more updatesMedicover AB (publ) to Report Fiscal Year 2025 Results on Feb 10, 2026Medicover AB (publ) announced that they will report fiscal year 2025 results at 7:45 AM, Central European Standard Time on Feb 10, 2026
お知らせ • Jun 19Medicover AB (Publ) Announces Executive ChangesMedicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service.
お知らせ • Jun 03Medicover Announces Positive Interim Results from the DART Clinical StudyMedicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort.
お知らせ • Apr 30+ 1 more updateMedicover AB (Publ) Approves Board ElectionsMedicover AB (publ) at its annual general meeting held on 29 April 2025, elected Michael Flemming and Claudia Olsson as new board member.
お知らせ • Apr 10Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million.Medicover AB (publ) (OM:MCOV B) acquired Cityfit Sp Z O O in a transaction valued at approximately PLN 570 million on April 8, 2025. The transaction values CityFit at PLN 565 million (approximately €131 million) including assumed net debt with right-of-use liabilities and implies approximately a 7x LTM EBITDA multiple (excluding synergies). It will be EPS accretive from day one after completion. CityFit has generated the revenue for 2024 amounted to approximately €32 million (PLN 136.92 million). Following the acquisition, Medicover owns over 170 fitness clubs across Poland. CityFit’s staff will join the Medicover family. Medicover AB (publ) (OM:MCOV B) completed the acquisition of Cityfit Sp Z O O on April 8, 2025.
お知らせ • Mar 22Medicover AB (publ) Proposes Dividend for 2024, Payable on 9 May 2025Medicover AB (publ) at its annual general meeting on 29 April 2025, board of directors proposed a dividend for 2024 of EUR 0.15 per share and 2 May 2025 as record date for dividend. Assuming this date will be the record date, Euroclear Sweden AB is expected to disburse dividends on 9 May 2025. The last day for trading in the company's share including the right to the dividend is 29 April 2025.
お知らせ • Feb 13Medicover AB (Publ) Proposes Dividend for 2024Medicover AB (publ) announced that its board of directors proposed a dividend for 2024 of €0.15 (€0.12) per share.
お知らせ • Feb 12Medicover AB (Publ) Announces CEO Changes, Effective 1 May 2025The Board of Directors of Medicover AB (publ) announced that John Stubbington will succeed Fredrik Rågmark as new CEO of the Medicover group from 1 May 2025. After 30 years with the Medicover group and 25 years as CEO, Fredrik Rågmark will step down from his operational role in Medicover by the end of April 2025 but will remain available to Medicover during 2025. John Stubbington, currently COO of Medicover'sHealthcare Services division, joined Medicover in 2010. Before joining Medicover, John held various positions within BUPA, the global health insurer, including nine years of working for their International division.
お知らせ • Oct 30+ 3 more updatesMedicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025Medicover AB (publ) announced that they will report first half, 2025 results on Jul 24, 2025
お知らせ • Oct 02Medicover AB (publ) Announces Nomination Committee for the AGM 2025Medicover AB (publ) publishes the nomination committee's composition for the annual general meeting in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding; Hans Ramel, NG Invest Beta AB; Jannis Kitsakis, Fjärde AP-Fonden; Sophie Larsén, AMF och AMF Fonder. AGM to be held on 29 April 2025. Proposals should be submitted to the nomination committee no later than 11 March 2025.
お知らせ • Oct 01Medicover AB (publ), Annual General Meeting, Apr 25, 2025Medicover AB (publ), Annual General Meeting, Apr 25, 2025.
お知らせ • Aug 14Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during fourth quarter of 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain - one of the leading brands within the Pepco Group (publ). Pepco Group is listed on the Warsaw stock exchange since 2021 with a market cap of over EUR 2.4 billion. Before Pepco, Anand held the position of head of finance at other retail chains such as Halfords and Argos. Anand Patel will replace Joe Ryan, who has served as CFO of Medicover for over 28 years and will be retiring, as announced last year.
お知らせ • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
お知らせ • Jan 09Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024Medicover announced that Kamila Skorupinski will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services.
お知らせ • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.
お知らせ • Nov 04Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial OfficerJoe Ryan, CFO, has announced that after 28 years with Medicover he will retire from the company during 2024. Joe Ryan will continue in the role until a successor is in place, ensuring continuity. A search process has started.
お知らせ • Sep 21Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024Medicover AB (publ) ("Medicover") publishes the nomination committee's composition for the annual general meeting in 2024. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 27 April 2023, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding, Hans Ramel, NG Invest Beta AB, Jannis Kitsakis, Fjärde AP-Fonden, Angelica Hanson, AMF och AMF Fonder.
お知らせ • Sep 20Medicover AB (publ), Annual General Meeting, Apr 26, 2024Medicover AB (publ), Annual General Meeting, Apr 26, 2024.
お知らせ • Jul 26+ 3 more updatesMedicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024Medicover AB (publ) announced that they will report Q1, 2024 results at 7:45 AM, Central European Standard Time on Apr 26, 2024
お知らせ • Feb 18Medicover AB (publ) Proposes Dividend for 2022Medicover AB (publ) board of directors proposed a dividend for 2022 of €0.12 (€0.12) per share.
お知らせ • Nov 03+ 2 more updatesMedicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023Medicover AB (publ) announced that they will report Q2, 2023 results on Jul 26, 2023
お知らせ • Oct 22Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Medicover AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023